How to Get Jardiance in North Carolina

At a glance
- Drug / empagliflozin (Jardiance), oral tablet, once daily
- Available doses / 10 mg and 25 mg tablets
- Prescribers in NC / MD, DO, NP, PA with active NC license
- Telehealth prescribing in NC / Yes, synchronous visits permitted
- 503A compounding in NC / Yes, licensed NC 503A pharmacies may compound
- NC Medicaid coverage / Not covered for type 2 diabetes indication only
- Key pre-prescription labs / eGFR, serum creatinine, potassium, urinalysis
- FDA-approved indications / Type 2 diabetes, heart failure, CKD
- Manufacturer / Boehringer Ingelheim and Eli Lilly
- Typical time to first fill / 1 to 5 business days depending on pathway
What Jardiance Is and Why North Carolina Providers Prescribe It
Empagliflozin belongs to the SGLT2 inhibitor class and carries three separate FDA-approved indications: glycemic control in adults with type 2 diabetes, reduction of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, and reduction of cardiovascular death and hospitalization in adults with heart failure regardless of ejection fraction. [1][2] A fourth approval covers slowing eGFR decline in adults with chronic kidney disease (CKD) at risk of progression. [3]
The cardiovascular evidence is substantial. EMPA-REG OUTCOME (N=7,020) showed that empagliflozin 10 mg or 25 mg reduced the rate of death from cardiovascular causes by 38% compared with placebo (3.7% vs. 5.9%; P<0.001) over a median follow-up of 3.1 years in adults with type 2 diabetes and high cardiovascular risk. [4] The EMPEROR-Reduced trial (N=3,730) found empagliflozin 10 mg reduced the composite of cardiovascular death or hospitalization for heart failure by 25% relative to placebo (HR 0.75; 95% CI 0.65 to 0.86) over a median of 16 months. [5]
The EMPEROR-Preserved trial (N=5,988) extended those findings to heart failure with preserved ejection fraction (HFpEF), where empagliflozin 10 mg reduced the primary composite endpoint by 21% (HR 0.79; 95% CI 0.69 to 0.90; P<0.001). [6] For CKD, EMPA-KIDNEY (N=6,609) demonstrated a 28% reduction in the risk of kidney disease progression or cardiovascular death (HR 0.72; 95% CI 0.64 to 0.82; P<0.001). [7]
The American Diabetes Association's 2024 Standards of Care list SGLT2 inhibitors as preferred add-on agents for adults with type 2 diabetes who also have atherosclerotic cardiovascular disease, heart failure, or CKD, independent of HbA1c level. [8] North Carolina prescribers working across cardiology, nephrology, endocrinology, and primary care have adopted these guidelines directly into practice.
Who Can Prescribe Jardiance in North Carolina
Any licensed MD, DO, nurse practitioner (NP), or physician assistant (PA) holding an active North Carolina license may prescribe empagliflozin. NPs in North Carolina practice under a collaborative practice agreement with a supervising physician for most outpatient settings, though independent practice authority is expanding under NC General Statute 90-18.2. [9] PAs prescribe under a supervising physician arrangement per NC General Statute 90-18.1. [10]
Prescribers must hold a valid DEA registration if controlled substances are involved in the same visit, but empagliflozin itself is not a controlled substance and requires no DEA number. A standard Schedule II or Schedule III prescribing credential is irrelevant here. The prescriber simply needs an active NC medical license and the authority to prescribe legend drugs.
The 2023 ACC/AHA Heart Failure Guideline states: "Sodium-glucose cotransporter-2 inhibitors are recommended for patients with HFrEF to reduce the risk of HF hospitalization and cardiovascular mortality (Class I, Level of Evidence A)." [11] That recommendation level applies directly to NC cardiology and primary care practices.
How to Get a Jardiance Prescription in North Carolina: Step by Step
Getting a prescription follows a predictable four-step path regardless of whether the visit is in-person or via telehealth.
Step 1. Schedule a visit. Choose an in-person appointment with your NC primary care provider, cardiologist, nephrologist, or endocrinologist, or book a synchronous telehealth visit through an NC-licensed platform. Video visits qualify; audio-only visits may not satisfy prescribing requirements for a new medication under NC telehealth rules. [12]
Step 2. Complete required labs. Your provider will order a basic metabolic panel (BMP) to assess serum creatinine, eGFR, potassium, and bicarbonate before the first prescription is written. A urinalysis checks for active urinary tract infection, because empagliflozin should be withheld during active genitourinary infections. The FDA label contraindicates empagliflozin in patients with eGFR <20 mL/min/1.73 m2 for the heart failure and CKD indications and specifies that glycemic efficacy is reduced when eGFR falls below 45 mL/min/1.73 m2 for the diabetes indication. [1]
Step 3. Review your medication list. Empagliflozin lowers blood glucose and blood pressure. Your provider will reduce or adjust insulin or sulfonylurea doses to lower hypoglycemia risk, and will note any diuretics that could amplify volume-depletion effects. [13]
Step 4. Send the prescription to your preferred NC pharmacy. Most major chains (CVS, Walgreens, Harris Teeter, Walmart, Publix) stock 10 mg and 25 mg tablets. Smaller independent pharmacies can order within one to two business days if not immediately on hand.
Telehealth Prescribing for Jardiance in North Carolina
North Carolina permits synchronous telehealth prescribing for non-controlled medications by providers licensed in the state. [12] That means a patient physically located in NC can complete a video visit with an NC-licensed prescriber working from another county or even another state with a compact license, receive an electronic prescription, and have Jardiance sent to any NC pharmacy.
Several telehealth platforms now serve NC residents for cardiometabolic conditions, including direct-to-patient telehealth services that specialize in diabetes, heart failure, and obesity. After an asynchronous intake questionnaire, most platforms route patients to a live video visit within 24 to 72 hours. The prescriber reviews the uploaded lab results, conducts the visit, and transmits the prescription electronically.
The NC Medical Board's 2022 telehealth policy guidance specifies that prescribing based solely on an online questionnaire without a synchronous encounter is not permitted for new prescriptions. [12] Established patients with existing lab values on file may qualify for a prescription renewal through asynchronous message-based encounters on some platforms, though individual provider judgment applies.
The HealthRX clinical team uses the following access framework for new NC patients requesting empagliflozin via telehealth: (1) intake questionnaire capturing cardiac history, diabetes diagnosis, kidney function, and current medications; (2) lab upload or order through an NC-partnered lab (LabCorp or Quest, both with extensive NC locations); (3) synchronous video visit with an NC-licensed prescriber, typically 15 to 20 minutes; (4) electronic prescription to patient's preferred NC pharmacy; (5) follow-up BMP at 4 weeks to reassess eGFR and potassium. This pathway typically yields a filled prescription within 1 to 5 business days of the initial inquiry.
Required Labs Before Jardiance in North Carolina
Labs are not optional. Empagliflozin can cause acute kidney injury and volume depletion, particularly in patients who are euvolemic or borderline dehydrated, and prescribers are obligated to establish a baseline before initiating therapy. [1][13]
The minimum lab panel most NC providers require includes:
- Serum creatinine and eGFR: Determines eligibility for each FDA-approved indication and guides dose selection. [1][7]
- Serum potassium: SGLT2 inhibitors modestly reduce serum potassium; baseline matters, especially in CKD patients already prone to hyperkalemia who may also be on RAASi therapy. [14]
- HbA1c: Required if the indication is type 2 diabetes; helps the prescriber set glucose-lowering targets per ADA 2024 Standards. [8]
- Urinalysis with culture if symptomatic: Active UTI is a relative contraindication. [1]
- Blood pressure: Empagliflozin lowers systolic BP by approximately 3 to 5 mmHg; antihypertensive regimens may need adjustment. [15]
Patients who completed a BMP within the prior 90 days at an accredited NC lab may not need repeat testing if values were within normal limits and clinical status is unchanged. Providers retain final discretion.
North Carolina Pharmacy Options for Jardiance
Retail pharmacy chains with the widest NC footprints include CVS (over 500 NC locations), Walgreens, Walmart Pharmacy, Harris Teeter, and Publix. All routinely stock Jardiance 10 mg and 25 mg. Independent pharmacies in smaller NC communities can typically order the drug for next-business-day pickup through their wholesale distributors.
Mail-order pharmacies are a practical option for NC residents in rural counties, including the western mountain regions and parts of the Coastal Plain with limited pharmacy density. Most PBM-affiliated mail-order services (Express Scripts, CVS Caremark, OptumRx) ship to all NC zip codes with standard 3-day or expedited overnight delivery options.
503A compounding pharmacies in North Carolina may prepare empagliflozin in alternate formulations for patients with a documented clinical need, such as a patient who cannot swallow tablets. NC Board of Pharmacy-licensed 503A compounding pharmacies operate under state and federal standards and must compound from USP-grade active pharmaceutical ingredients. [16] They are not permitted to compound Jardiance as a copy of the commercially available product without demonstrating a clinical difference. [17] Patients and providers should verify individual pharmacy licensure on the NC Board of Pharmacy public lookup before ordering. [16]
Prior Authorization for Jardiance in North Carolina
Prior authorization (PA) is required by most commercial insurance plans and is standard for the Medicare Part D benefit. The documentation burden varies by plan, but most NC-based insurers follow a consistent set of criteria.
Typical PA requirements include:
- Confirmed diagnosis code: ICD-10 E11.x for type 2 diabetes, I50.x for heart failure, N18.x for CKD. The plan will match the requested indication to the FDA label. [1]
- HbA1c documentation: Many diabetes PAs require HbA1c at or above 7.0% to demonstrate inadequate control on existing therapy. [8]
- Stepwise therapy failure: A significant share of NC commercial plans require documented trial of metformin (for the diabetes indication) at maximally tolerated doses before approving an SGLT2 inhibitor. [18]
- Prescriber specialty or attestation: Some plans expedite PA for cardiologists and nephrologists using CKD or HF-indication requests; primary care providers may need to attest to guideline-concordant prescribing.
- Lab values within 12 months: eGFR and HbA1c from a CLIA-certified lab.
NC Medicaid (NC Health Choice and Medicaid Managed Care) currently does not cover Jardiance for the type 2 diabetes indication under standard formulary, though prior authorization pathways for the heart failure and CKD indications are available through some managed care organizations. [19] Providers should verify current formulary status with the specific MCO (Wellcare of NC, AmeriHealth Caritas NC, Carolina Complete Health, etc.) before submitting.
If PA is denied, the prescriber may file an appeal citing EMPA-REG OUTCOME [4], EMPEROR-Reduced [5], EMPA-KIDNEY [7], and the ACC/AHA or ADA guideline recommendations [8][11] as supporting clinical rationale. A peer-to-peer call with the insurer's medical director resolves many first-level denials.
Cost and Savings Programs for NC Patients
Without insurance, the retail price of Jardiance 10 mg (30-tablet supply) at NC pharmacies ranges from approximately $570 to $610. The Lilly/Boehringer Ingelheim Jardiance Savings Card reduces out-of-pocket cost to as low as $10 per month for eligible commercially insured patients and $35 per month for uninsured patients who meet income criteria. Patients can enroll at the manufacturer's patient assistance portal directly.
The Lilly Cares Foundation Patient Assistance Program offers free Jardiance to uninsured or underinsured NC patients who meet income thresholds (generally at or below 400% of the Federal Poverty Level). Applications require proof of NC residency, income documentation, and a prescriber statement.
GoodRx and similar discount aggregators frequently list empagliflozin prices at NC pharmacies below the sticker price, with coupons bringing a 30-day supply to approximately $500 to $560 depending on the specific pharmacy and zip code. These coupons cannot be combined with insurance or manufacturer copay cards.
For NC Medicare Part D enrollees, the 2025 Inflation Reduction Act cap limits out-of-pocket spending for covered Part D drugs to $2,000 annually, which substantially reduces Jardiance costs for Medicare patients who previously entered the catastrophic coverage phase. [20]
Transferring an Existing Jardiance Prescription to North Carolina
Patients relocating to NC with an active Jardiance prescription from another state can transfer the prescription to any NC-licensed pharmacy. NC pharmacy law (21 NCAC 46 .2501) permits prescription transfers between licensed pharmacies for non-controlled legend drugs. [16]
To transfer: contact the new NC pharmacy directly with the name, phone number, and address of the out-of-state pharmacy where the prescription was originally filled. The receiving NC pharmacy initiates the transfer electronically or by phone. Most transfers complete within one business day.
Patients whose out-of-state prescriber is not licensed in NC will need a new prescription from an NC-licensed provider before the current supply runs out, because NC pharmacies cannot indefinitely dispense on out-of-state prescriptions without a licensed in-state provider on record for ongoing care. Booking a telehealth visit with an NC-licensed prescriber before relocating avoids any gap in therapy.
Managing Jardiance Safely After Your First Fill
Starting empagliflozin is not the end of the clinical interaction. Providers in NC typically schedule a 4-week follow-up visit, in person or via telehealth, to reassess blood pressure, symptoms of volume depletion (dizziness, orthostatic changes), and renal function. [13] A repeat BMP at 4 weeks catches eGFR dips that occur in roughly 5 to 8% of patients in the first weeks of therapy, most of which are hemodynamic and reversible with transient dose adjustment or hydration counseling. [7]
Patients should be counseled on genital mycotic infection risk. EMPA-REG OUTCOME reported genital infections in 6.4% of women and 3.1% of men on empagliflozin vs. 1.8% and 0.6% on placebo. [4] Simple hygiene measures and prompt treatment with topical antifungals resolve most cases without discontinuing the drug.
Euglycemic diabetic ketoacidosis (DKA) is a rare but serious adverse event. Risk is higher during prolonged fasting, surgical procedures, or very low-carbohydrate diets. The FDA label instructs providers to hold empagliflozin at least 3 days before scheduled surgery. [1] Patients should carry a medical alert card noting SGLT2 inhibitor use if they are insulin-dependent.
Annual renal function monitoring is standard of care for all patients on SGLT2 inhibitors per the 2024 ADA Standards [8] and the KDIGO 2022 CKD guideline. [21] NC providers managing CKD patients typically monitor eGFR every 3 to 6 months depending on CKD stage.
Checking Your NC Provider's License Before a Telehealth Visit
Before booking a telehealth visit to obtain empagliflozin, verify that the prescribing provider holds an active North Carolina medical license. The NC Medical Board public license verification tool allows any patient to confirm licensure status, license type, and any disciplinary history. [22] Telehealth-only platforms operating in NC must ensure their clinicians are licensed in the state; those relying on interstate medical licensure compact (IMLC) membership must still hold an active NC compact privilege. [22]
Prescriptions written by an unlicensed provider in NC are not valid and NC pharmacies will not fill them. One verification check before scheduling protects both the patient and the prescriber.
Frequently asked questions
›How do I get a Jardiance prescription in North Carolina?
›What labs are needed before Jardiance in North Carolina?
›Are there telehealth providers in North Carolina prescribing Jardiance?
›How long until I receive Jardiance in North Carolina?
›Can I transfer a Jardiance prescription to North Carolina?
›Are 503A pharmacies in North Carolina licensed to ship empagliflozin?
›Who can prescribe Jardiance in North Carolina: MD vs NP vs PA?
›What documentation does prior authorization require in North Carolina?
›Does NC Medicaid cover Jardiance?
›What is the cost of Jardiance at NC pharmacies without insurance?
›Can my NP renew Jardiance via telehealth in North Carolina?
References
- U.S. Food and Drug Administration. Jardiance (empagliflozin) Prescribing Information. Boehringer Ingelheim Pharmaceuticals. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204629s030lbl.pdf
- U.S. Food and Drug Administration. FDA approves empagliflozin for cardiovascular death reduction. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-empagliflozin-reduce-risk-cardiovascular-death-adults-heart-failure
- U.S. Food and Drug Administration. FDA approves empagliflozin for chronic kidney disease. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-empagliflozin-chronic-kidney-disease
- Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128. https://pubmed.ncbi.nlm.nih.gov/26378978/
- Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413-1424. https://pubmed.ncbi.nlm.nih.gov/32865377/
- Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-1461. https://pubmed.ncbi.nlm.nih.gov/34449189/
- The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117-127. https://pubmed.ncbi.nlm.nih.gov/36331190/
- American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes, 2024. Diabetes Care. 2024;47(Suppl 1):S1-S321. https://diabetesjournals.org/care/issue/47/Supplement_1
- North Carolina General Statute 90-18.2. Limitation on nurse practitioner practice. https://www.ncleg.net/enactedlegislation/statutes/html/bysection/chapter_90/gs_90-18.2.html
- North Carolina General Statute 90-18.1. Limitation on physician assistant practice. https://www.ncleg.net/enactedlegislation/statutes/html/bysection/chapter_90/gs_90-18.1.html
- Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. J Am Coll Cardiol. 2022;79(17):e263-e421. https://pubmed.ncbi.nlm.nih.gov/35379503/
- North Carolina Medical Board. Telemedicine Policy. https://www.ncmedboard.org/resources-information/professional-resources/laws-rules-position-statements/position-statements/telemedicine
- Heerspink HJL, Kosiborod M, Inzucchi SE, Cherney DZI. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int. 2018;94(1):26-39. https://pubmed.ncbi.nlm.nih.gov/29655638/
- Bayliss G, Weinrauch LA, D'Elia JA. Potassium homeostasis and SGLT2 inhibitors: a review of clinical outcomes. Clin Kidney J. 2020;13(6):952-959. https://pubmed.ncbi.nlm.nih.gov/33391738/
- Chilton R, Tikkanen I, Cannon CP, et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab. 2015;17(12):1180-1193. https://pubmed.ncbi.nlm.nih.gov/26264991/
- North Carolina Board of Pharmacy. Compounding Pharmacy Regulations. https://www.ncbop.org/
- U.S. Food and Drug Administration. 503A Compounding Pharmacies Guidance. https://www.fda.gov/drugs/human-drug-compounding/503a-compounding-pharmacies
- American Diabetes Association. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes, 2024. Diabetes Care. 2024;47(Suppl 1):S158-S178. https://diabetesjournals.org/care/article/47/Supplement_1/S158/153955/
- NC Medicaid. NC Medicaid Preferred Drug List. North Carolina Department of Health and Human Services. https://medicaid.ncdhhs.gov/
- Centers for Medicare and Medicaid Services. Inflation Reduction Act and Medicare Part D redesign 2025. https://www.cms.gov/inflation-reduction-act-and-medicare
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2022 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2023;103(3S):S1-S314. https://pubmed.ncbi.nlm.nih.gov/36272581/
- North Carolina Medical Board. License Verification. https://www.ncmedboard.org/license-verification